.Clinigen becomes sole license holder of Novartis\' cancer drug Proleukin in $210m deal httpbit.ly2Dyz9Vq pharmapic.twitter.comTu43ykbNcT

.@Clinigen becomes sole license holder of @Novartis' #cancer drug Proleukin in $210m deal http://bit.ly/2Dyz9Vq  #pharmapic.twitter.com/Tu43ykbNcT

06:45 EST 14 Feb 2019 | Pharmafile

. @Clinigen becomes sole license holder of @Novartis' #cancer drug Proleukin in $210m deal http://bit.ly/2Dyz9Vq  #pharma pic.twitter.com/Tu43ykbNcT

More From BioPortfolio on ".@Clinigen becomes sole license holder of @Novartis' #cancer drug Proleukin in $210m deal http://bit.ly/2Dyz9Vq  #pharmapic.twitter.com/Tu43ykbNcT"